GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Syngen Biotech Co 8279.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

81.80

+1.87%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 2.14bn

FY2016FY2025

Net income

TWD 271.6m

FY2016FY2025

Free cash flow

TWD 243.1m

FY2016FY2025

Shareholders' equity

TWD 2.37bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 2.14bnTWD 2.01bnTWD 1.84bnTWD 1.93bnTWD 1.47bnTWD 1.31bnTWD 1.30bnTWD 1.08bnTWD 955.6mTWD 769.4m
Gross profitTWD 723.6mTWD 723.9mTWD 643.9mTWD 688.2mTWD 528.3mTWD 495.4mTWD 486.1mTWD 377.4mTWD 356.2mTWD 283.3m
Research and developmentTWD 60.6mTWD 59.3mTWD 46.8mTWD 45.3mTWD 49.5mTWD 43.3mTWD 52.9mTWD 45.5mTWD 39.8mTWD 42.9m
Operating incomeTWD 338.1mTWD 310.2mTWD 341.2mTWD 400.9mTWD 298.4mTWD 259.3mTWD 242.9mTWD 166.1mTWD 172.5mTWD 115.8m
Net incomeTWD 271.6mTWD 240.2mTWD 274.8mTWD 321.2mTWD 237.8mTWD 215.6mTWD 188.8mTWD 134.0mTWD 148.6mTWD 90.2m
Diluted earnings per share10.028.8610.1411.858.777.947.855.656.274.16

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 3.05bnTWD 3.08bnTWD 3.11bnTWD 3.07bnTWD 2.42bnTWD 2.13bnTWD 1.93bnTWD 1.30bnTWD 1.16bnTWD 1.05bn
Cash and short-term investments—————TWD 423.4mTWD 519.4mTWD 128.5mTWD 171.2mTWD 249.4m
Total liabilitiesTWD 674.9mTWD 848.5mTWD 974.6mTWD 1.08bnTWD 644.2mTWD 500.7mTWD 437.0mTWD 427.9mTWD 400.0mTWD 413.9m
DebtTWD 4.9mTWD 163.9mTWD 223.0mTWD 182.0mTWD 50.0mTWD 250.3mTWD 153.4mTWD 167.3mTWD 167.3mTWD 22.7m
Shareholders' equityTWD 2.37bnTWD 2.24bnTWD 2.13bnTWD 1.99bnTWD 1.77bnTWD 1.63bnTWD 1.49bnTWD 873.1mTWD 764.0mTWD 637.3m
Shares outstanding27m27m27m27m27m27m24m24m24m22m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsTWD 319.5mTWD 348.0mTWD 415.1mTWD 277.5mTWD 336.5m—TWD 255.2mTWD 66.7mTWD 160.8mTWD 47.0m
Capital spending−TWD 76.4m−TWD 64.3m−TWD 93.8m−TWD 584.7m−TWD 61.7m—−TWD 67.2m−TWD 64.7m−TWD 196.0m−TWD 19.6m
Free cash flowTWD 243.1mTWD 283.7mTWD 321.3m−TWD 307.2mTWD 274.8m—TWD 188.1mTWD 2.0m−TWD 35.2mTWD 27.4m
Dividends paid−TWD 135.5m−TWD 135.5m−TWD 135.5m−TWD 108.4m−TWD 94.9m—−TWD 57.8m−TWD 21.0m−TWD 21.0m−TWD 9.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 593.4mTWD 416.7mTWD 479.8mTWD 563.2mTWD 607.6mTWD 485.9mTWD 474.8mTWD 555.6m
Gross profitTWD 186.7mTWD 137.4mTWD 134.7mTWD 194.7mTWD 220.3mTWD 173.9mTWD 171.0mTWD 235.0m
Operating incomeTWD 83.7mTWD 43.3m—TWD 99.7mTWD 113.2mTWD 77.6m—TWD 94.5m
Net incomeTWD 69.7mTWD 33.4mTWD 37.9mTWD 85.0mTWD 87.5mTWD 61.1mTWD 58.4mTWD 72.3m
Diluted earnings per share2.571.231.403.133.232.262.162.67
Cash from operations−TWD 81.0mTWD 118.0mTWD 74.0mTWD 181.0m—TWD 63.0mTWD 143.0mTWD 170.0m
Capital spending−TWD 30.0m−TWD 6.0m−TWD 23.0m−TWD 6.0m−TWD 25.0m−TWD 20.0m−TWD 10.0m−TWD 9.0m
Free cash flow−TWD 111.0mTWD 112.0mTWD 51.0mTWD 175.0m—TWD 43.0mTWD 133.0mTWD 161.0m
Total assetsTWD 3.16bnTWD 3.06bnTWD 3.05bnTWD 3.07bnTWD 3.13bnTWD 3.07bnTWD 3.08bnTWD 3.00bn
Cash and short-term investments———TWD 283.2m————
Debt——TWD 4.9mTWD 223.4mTWD 34.4mTWD 49.2mTWD 163.9mTWD 178.7m
Shareholders' equityTWD 2.34bnTWD 2.27bnTWD 2.37bnTWD 2.33bnTWD 2.25bnTWD 2.16bnTWD 2.24bnTWD 2.18bn

Financial ratios

Data as of 24 Oct 2026

FY2025FY2024FY2023FY2022FY2021
Gross margin33.9%41.6%35.0%35.6%35.9%
Operating margin15.9%15.3%18.7%20.8%19.2%
Net margin12.7%11.9%15.0%16.6%16.2%
Return on equity11.4%10.7%12.9%16.1%13.4%
Return on assets8.9%7.8%8.8%10.5%9.8%
Revenue growth6.1%9.6%-4.8%31.2%—
Earnings growth13.1%-12.6%-14.4%35.1%—
Current ratio2.20x2.22x1.94x1.55x2.43x
Debt to equity0.00x0.07x0.10x0.09x0.03x
Equity ratio77.9%72.5%68.6%64.9%73.3%
Interest coverage60.23x33.30x38.68x79.17x87.84x
R&D as a share of sales2.8%2.9%2.5%2.3%3.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue3.4%10.3%12.7%
Operating income-5.5%5.5%15.1%
Net income-5.4%4.7%15.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin34.9%35.1%35.5%35.8%
Operating margin15.6%17.6%18.2%17.7%
Net margin12.3%14.0%14.6%14.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings11.614.315.813.712.913.615.016.721.822.0
Price to sales1.51.72.42.32.12.22.22.13.42.6

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 26 Jun 2025.

FY2025FY2024FY2023FY2022
Paid in the year5.005.005.004.00
  • 1100-for-1000 split · 9 Jul 2018

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.